Acanthosis Nigricans: The Dark Skin Patches That Signal Insulin Resistance
Across India, millions of people carry a visible, unmistakeable metabolic signal on their skin without knowing what it means. Dark, velvety, thickened patches in the creases of the neck, underarms, groin, or under the breasts — commonly attributed to inadequate scrubbing, skin darkening from friction, or simply "my skin type" — are in many cases a dermatological condition called acanthosis nigricans (AN). And acanthosis nigricans, when present in the context of overweight or metabolic risk, is one of the most reliable cutaneous indicators of insulin resistance and impending or established Type 2 diabetes. This article explains the science behind the condition, how to recognise it, and what it should prompt you to do.
What Is Acanthosis Nigricans? Appearance and Distribution
Acanthosis nigricans presents as hyperpigmented, hyperkeratotic (thickened), velvety-textured skin in areas where skin folds naturally — the posterior and lateral neck, the axillae (underarms), the groin and inner thighs, the antecubital fossae (inner elbows), and beneath the breasts. The texture is a critical distinguishing feature: AN does not simply look darker, it feels different — thicker and velvety to the touch, as though the skin has accumulated extra layers. It is not raised into distinct bumps or plaques; rather, it is a diffuse, blended thickening across a skin fold area.
In Indian patients with darker baseline skin tones, the discolouration of AN can be less dramatic than it appears in clinical photographs taken in populations with lighter skin. This means it is frequently overlooked or attributed to natural skin variation. The texture change — the velvet-like thickening — is often the more reliable diagnostic feature than pigmentation alone for clinicians working with Indian patients. The neck is the most important site to examine: posterior neck AN (affecting the skin at the nape of the neck) is the most consistent location across all patient groups.
The Biology: Why Insulin Resistance Produces Dark Skin Patches
The pathophysiology of acanthosis nigricans directly reflects the hyperinsulinaemia of insulin resistance. In a person whose cells do not respond adequately to insulin, the pancreas compensates by secreting more and more insulin to maintain glucose homeostasis. Circulating insulin levels become chronically elevated — sometimes 5–10 times normal fasting levels — even when blood glucose appears only mildly elevated or still within the normal range.
At these elevated concentrations, insulin "cross-activates" insulin-like growth factor 1 (IGF-1) receptors on keratinocytes (epidermal skin cells) and dermal fibroblasts. IGF-1 receptors, when stimulated, drive rapid cell proliferation. In the skin, this produces two observable changes: increased epidermal thickness (hyperkeratosis — the velvet-like texture) and increased melanin production as a secondary consequence of accelerated cell turnover and inflammation (the hyperpigmentation). Both changes are directly caused by the trophic (growth-stimulating) effect of excess insulin acting on skin cells.
This explains a critical clinical point: no amount of topical skin brightening or exfoliation will clear acanthosis nigricans in a person with active insulin resistance. The skin is continuously receiving a growth signal from hyperinsulinaemia. Removing surface pigment without addressing the circulating insulin excess is equivalent to repainting a wall while the moisture causing the peeling is still present. The condition will reassert itself because the driver is systemic and ongoing.
What Acanthosis Nigricans Tells You About Metabolic Risk
The presence of AN in a person who is overweight or obese is a strong predictor of impaired fasting glucose, metabolic syndrome, and future Type 2 diabetes. Studies in Indian adults have found that the sensitivity of AN as a marker of insulin resistance ranges from 68% to 90%, with specificity above 80% when assessed in the appropriate demographic context. In Indian children and adolescents, where Type 2 diabetes and insulin resistance are presenting at younger ages than ever before due to rising obesity rates, AN is often the first visible sign of a metabolic trajectory that will lead to diabetes if not addressed.
In a person with established Type 2 diabetes, the degree of AN can serve as a rough proxy for insulin resistance severity and glycaemic control. As insulin resistance improves through weight loss, increased physical activity, metformin therapy, or insulin-sensitising medications, circulating insulin levels decrease, the IGF-1 receptor stimulation on keratinocytes diminishes, and the AN patches gradually lighten and soften. This resolution is not instant — skin cell turnover takes weeks to months — but it is measurable and clinically verifiable.
AN is rarely associated with Type 1 diabetes, for the simple reason that Type 1 patients lack endogenous insulin production and do not experience hyperinsulinaemia. When AN does appear in a Type 1 patient, it typically reflects insulin resistance developing alongside Type 1 diabetes — a combination called "double diabetes" or "Type 3c" — often in the context of weight gain from high-dose exogenous insulin or concurrent metabolic factors.
When Acanthosis Nigricans Signals Something More Serious
While insulin resistance is by far the most common cause of AN in the Indian population, it is important to be aware that in a small subset of patients — particularly older adults who develop AN rapidly, who have no obvious metabolic risk factors, or in whom the patches appear in unusual locations such as the lips, palms, or mucous membranes — acanthosis nigricans can be a paraneoplastic sign. Paraneoplastic AN is caused by tumour-derived growth factors activating the same IGF-1 receptors in skin, and is most commonly associated with gastric adenocarcinoma. Rapid-onset, extensive, or atypical AN warrants prompt medical evaluation beyond a simple metabolic workup.
Certain medications also cause AN as an adverse effect. High-dose niacin (nicotinic acid), systemic corticosteroids, and some hormonal treatments have been reported to produce AN-like skin changes. When AN develops in the context of a new medication, reviewing the drug's cutaneous side-effect profile is important before attributing the skin change to insulin resistance alone.
Practical Management: What to Do If You Have Acanthosis Nigricans
The first and most important step is metabolic investigation. Any adult in India who notices AN — particularly in the neck, underarms, or groin — should undergo fasting blood glucose, fasting insulin, and an HbA1c test. An HOMA-IR (homeostatic model assessment of insulin resistance) calculation from these values quantifies the degree of insulin resistance. A lipid panel (to assess for concurrent dyslipidaemia) and blood pressure measurement complete a basic metabolic screen. This investigation should not be delayed by months of topical treatment.
The foundational treatment is lifestyle intervention. Weight loss of even 5–10% of body weight produces measurable improvements in insulin sensitivity and, over months, visible lightening of AN. Increased aerobic physical activity, dietary reduction of refined carbohydrates and ultraprocessed foods, and where appropriate, metformin therapy (prescribed by a physician) address the hyperinsulinaemia at its source. These are the only interventions proven to consistently improve AN over time.
From a skincare standpoint, the goal is not to "remove" the AN (which topicals cannot do) but to manage the texture, prevent secondary irritation, and maintain barrier health in the affected skin folds. Gentle exfoliation with low-concentration urea (10%) or lactic acid (5–12%) can reduce the scale and roughness of hyperkeratotic AN skin without disrupting the barrier. Avoid aggressive scrubbing, which can cause post-inflammatory hyperpigmentation on top of the existing AN, worsening the appearance. Keep skin folds clean and dry to prevent secondary intertrigo or candidal infection, which commonly develop in the moist environment of thickened AN skin folds.
Topical retinoids and keratolytic preparations prescribed by a dermatologist may improve the texture and reduce the thickness of AN over time. Topical skin lighteners (niacinamide, alpha-arbutin, kojic acid) may offer modest cosmetic improvement by reducing melanin synthesis in the affected keratinocytes, but will not resolve the condition while insulin resistance persists. Movataa's diabetic body care formulations — fragrance-free and barrier-appropriate — are suitable for maintaining skin health in and around AN-affected areas, supporting hydration and reducing the irritation that friction in skin folds commonly causes.
Conclusion
Acanthosis nigricans is not a cosmetic inconvenience or a hygiene failure — it is a metabolic signal written in the skin, indicating that insulin resistance is present and that diabetes risk is elevated. Recognising it accurately, investigating it appropriately, and treating its metabolic cause rather than its cosmetic appearance are the three essential responses. The skin is telling you something important; the right response is to listen.
For skincare that supports diabetic and metabolically complex skin every day, explore Movataa's full diabetic skincare range — formulated for Indian patients at every stage of their metabolic health journey.
